Claims for Patent: 10,081,657

Summary for Patent: 10,081,657

Title:	Biosynthetic proline/alanine random coil polypeptides and their uses
Abstract:	The present invention relates to a biosynthetic random coil polypeptide or a biosynthetic random coil polypeptide segment or biosynthetic conjugate, in which the biosynthetic random coil polypeptide, the biosynthetic random coil polypeptide segment, or the biosynthetic conjugate comprises an amino acid sequence consisting solely of proline and alanine amino acid residues, wherein the amino acid sequence consists of at least about 50 proline (Pro) and alanine (Ala) amino acid residues. The at least about 50 proline (Pro) and alanine (Ala) amino acid residues may be (a) constituent(s) of a heterologous polypeptide or an heterologous polypeptide construct. Also uses and methods of use of these biosynthetic random coil polypeptides or polypeptide segments or conjugates are described.
Inventor(s):	Skerra; Arne (Freising, DE), Binder; Uli (Freising, DE), Schlapschy; Martin (Freising, DE)
Assignee:	TECHNISCHE UNIVERSITAT MUNCHEN (Munich, DE) XL-PROTEIN GMBH (Freising, DE)
Application Number:	14/939,626
Patent Claims:	1. A drug conjugate comprising (i) a biosynthetic random coil polypeptide or polypeptide segment comprising an amino acid sequence consisting of proline and alanine amino acid residues, wherein said amino acid sequence consists of at least 150 proline (Pro) and alanine (Ala) amino acid residues, and (ii) a drug selected from the group consisting of (a) a biologically active protein or a polypeptide that comprises or that is an amino acid sequence that has or mediates a biological activity and (b) a small molecule drug. 2. The drug conjugate according to claim 1, wherein said random coil polypeptide or polypeptide segment comprises an amino acid sequence consisting of 150 to 3000 amino acid residues. 3. The drug conjugate according to claim 1, wherein said proline residues constitute more than 10% and less than 75% of the amino acid sequence. 4. The drug conjugate according to claim 1, wherein said random coil polypeptide or polypeptide segment comprises a plurality of amino acid repeats, wherein said repeat consists of proline and alanine residues and wherein no more than 6 consecutive amino acid residues are identical. 5. The drug conjugate according to claim 1, wherein said random coil polypeptide or polypeptide segment comprises an amino acid sequence selected from the group consisting of TABLE-US-00009 (SEQ ID NO: 1) AAPAAPAPAAPAAPAPAAPA; (SEQ ID NO: 2) AAPAAAPAPAAPAAPAPAAP; (SEQ ID NO: 3) AAAPAAAPAAAPAAAPAAAP; (SEQ ID NO: 4) AAPAAPAAPAAPAAPAAPAAPAAP; (SEQ ID NO: 5) APAAAPAPAAAPAPAAAPAPAAAP; (SEQ ID NO: 6) AAAPAAPAAPPAAAAPAAPAAPPA; and (SEQ ID NO: 51) APAPAPAPAPAPAPAPAPAP or circular permuted versions or (a) multimers(s) of these sequences as a whole or parts of these sequences. 6. The drug conjugate according to claim 1, wherein said polypeptide with biological activity, said biologically active protein or said polypeptide that comprises or that is an amino acid sequence that has or that mediates a biological activity is selected from the group consisting of binding proteins, antibody fragments, cytokines, growth factors, hormones or enzymes. 7. The drug conjugate of claim 6, wherein said polypeptide with biological activity is a binding protein and wherein said binding molecule is selected from the group consisting of antibodies, Fab fragments, F(ab').sub.2 fragments, CDR-derived peptidomimetics, single chain variable fragments (scFv), domain antibodies, lectins, immunoglobulin domains, fibronectin domains, protein A domains, SH3 domains, ankyrin repeat domains, and lipocalins. 8. The drug conjugate of claim 1, wherein said biologically active protein is selected from the group consisting of granulocyte colony stimulating factor, human growth hormone, alpha-interferon, beta-interferon, gamma-interferon, tumor necrosis factor, erythropoietin, coagulation factor VIII, gp120/gp160, soluble tumor necrosis factor I and II receptor, reteplase, exendin-4, anakinra, interleukin-2, neutrophil gelatinase-associated lipocalin, follicle-stimulating hormone, glucocerebrosidase, thymosin alpha 1, glucagon, somatostatin, adenosine deaminase, interleukine 11, coagulation factor VIIa, coagulation factor IX, hematide, lambda-interferone, leptin, interleukine-22 receptor subunit alpha (IL-22ra), interleukine-22, hyaluronidase, fibroblast growth factor 18, fibroblast growth factor 21, glucagon-like peptide 1, osteoprotegerin, IL-18 binding protein, growth hormone releasing factor, soluble TACI receptor, thrombospondin-1, soluble VEGF receptor Flt-1, and IL-4 mutein. 9. The drug conjugate according to claim 1, whereby said biosynthetic random coil polypeptide or polypeptide mediates an increased in vivo and/or in vitro stability of said drug conjugate. 10. The drug conjugate according to claim 9, wherein said increased in vivo stability is a prolonged plasma half-life of said drug conjugate when compared to the stability of a control polypeptide or a control conjugate lacking said random coil random coil polypeptide or polypeptide segment. 11. The drug conjugate according to claim 1, wherein said small molecule is selected from the group consisting of digoxigenin, fluorescein, doxorubicin, calicheamicin, camptothecin, fumagillin, dexamethasone, geldanamycin, paclitaxel, docetaxel, irinotecan, cyclosporine, buprenorphine, naltrexone, naloxone, vindesine, vancomycin, risperidone, aripiprazole, palonosetron, granisetron, cytarabine NX1838, leuprolide, goserelin, buserelin, octreotide, teduglutide, cilengitide, abarelix, enfuvirtide, ghrelin, alpha 4 integrin inhibitors, antisense nucleic acids, small interference RNAs, micro RNAs, steroids, DNA or RNA aptamers and peptides and/or peptidomimetics. 12. A composition comprising the drug conjugate according to claim 1. 13. The composition according to claim 12 which is a pharmaceutical composition or a diagnostic composition, optionally further comprising a pharmaceutically acceptable carrier(s). 14. The drug conjugate according to claim 1, wherein the biologically active protein is selected from the group consisting of binding proteins, antibody fragments, cytokines, growth factors, hormones and enzymes.

Details for Patent 10,081,657

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Bausch & Lomb Incorporated	VITRASE	hyaluronidase	Injection	021640	05/05/2004		2030-05-21
Bausch & Lomb Incorporated	VITRASE	hyaluronidase	Injection	021640	12/02/2004		2030-05-21
Amphastar Pharmaceuticals, Inc.	AMPHADASE	hyaluronidase	Injection	021665	10/26/2004		2030-05-21